Kiyatec, a number one biotechnology firm specializing in 3D cell tradition expertise, is happy to announce the promotion of Eric Perreault to the place of chief government officer (CEO).
Eric Perreault Position
As CEO, Eric Perreault will proceed to steer Kiyatec in its mission to revolutionize most cancers care by harnessing the facility of useful precision drugs with its KIYA-Predict™ and 3D Predict™ platforms. He succeeds Matt Gevaert, PhD, who after greater than 15 years as CEO will stay a member of Kiyatec’s Board of Administrators.
“We’re excited to announce Eric Perreault as the brand new CEO of Kiyatec. Eric’s management and intensive understanding of each our expertise and trade are belongings that may drive Kiyatec’s continued progress. We’re assured that, below Eric’s steerage, Kiyatec will make a significant and enduring contribution to most cancers therapy and drug discovery.”
As President of Kiyatec, Eric has been an integral a part of the Kiyatec workforce and has performed an important function in shaping the corporate’s strategic course. Together with his intensive trade expertise and management acumen, Eric’s promotion to CEO marks a major milestone in Kiyatec’s journey. On this new place, Eric will propel Kiyatec towards industrial success by driving innovation, forging strategic partnerships, and increasing market attain.
Eric Perreault on His New Position
“In my new function as CEO, my mission is to drive Kiyatec towards actually revolutionizing most cancers care, particularly for sufferers battling mind most cancers, who haven’t seen any actual therapy advances in a long time,” stated Eric. “I’m desirous to proceed collaborating with Matt as a member of our board and tapping into his intensive expertise to propel us towards conducting this formidable aim.”
As Kiyatec prepares for its subsequent section of progress and enlargement, the corporate stays targeted on advancing useful precision oncology with its 3D cell tradition expertise. With Eric Perreault as CEO, Kiyatec is well-positioned to spearhead transformative change in most cancers care, in the end driving enhancements in affected person outcomes.